KLI
NBIX icon

Kelman-Lazarov Inc’s Neurocrine Biosciences NBIX Stock Holding History

Kelman-Lazarov Inc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-60
Closed -$3.02K – 341
2016
Q3 		$3.02K Hold
60
– – ﹤0.01% 330
2016
Q2 		$2.72K Hold
60
– – ﹤0.01% 322
2016
Q1 		$2K Buy
+60
New +$2.38K ﹤0.01% 325

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kelman-Lazarov Inc's NBIX Position: Q4 2016 in Review

Kelman-Lazarov Inc sold out of Neurocrine Biosciences (NBIX) in Q4 2016, closing a stake of 60 shares — an estimated $3.02K sold.

Kelman-Lazarov Inc first reported a position in NBIX in Q1 2016 and held it in 3 quarters. The position peaked at $3.02K in Q3 2016. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

  • Kelman-Lazarov Inc reported no remaining Neurocrine Biosciences position as of Q4 2016 after selling out during the quarter.
  • Kelman-Lazarov Inc sold 60 Neurocrine Biosciences shares in Q4 2016, an estimated $3.02K.
  • Kelman-Lazarov Inc first reported a position in Neurocrine Biosciences in Q1 2016 and held it in 3 quarters.
  • Kelman-Lazarov Inc's Neurocrine Biosciences position peaked at $3.02K in Q3 2016.
  • 225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on Kelman-Lazarov Inc's 13F filing for Q4 2016, filed 17 Jan 2017.